Company profile
Bloomios, Inc.
OTC: BLMS · Healthcare · Medical - Pharmaceuticals
#689 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 14GM —SS 46
v0.1 · 25/100 weight · pillars only
↑ listing tenure, operating margin · ↓ Altman-Z, filing timeliness
Methodology →Revenue TTM
$8.2M
Rev growth YoY (TTM)
+46.5%
Net income (FY)
-$13.8M
Employees
23
as of 2026-08-30
Market cap
$19.3k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.1M$6.1M2022
Net income-$13.8M-$13.8M2022
Operating income-$4.1M-$4.1M2022
Total assets$26.0M$26.0M2022
Liabilities$27.3M$27.3M2022
Equity-$1.3M-$1.3M2022
Revenue trend
FY2020 – FY2022 · USD
FY20
FY20
FY21
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bloomios, Inc.’s revenue?
Bloomios, Inc. booked $6.1M in FY2022 revenue, contracting 28% year over year — slower than 75% of Healthcare companies we track, at a -226.7% net margin.
Peers · Healthcare
Decision Diagnostics Corp.——bioAffinity Technologies, Inc.32DOracle Healthcare Acquisition Corp.——Australis Capital Inc.——Lancer Orthodontics, Inc.——Abeona Therapeutics Inc.69BNeighbors
Santa Barbara →Key facts
CEOMichael Hill
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersSanta Barbara, CA
ExchangeOTC: BLMS
Employees23
IPO date2003-04-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.